HOME >> MEDICINE >> NEWS
Immunex Files Supplemental NDA for NOVANTRONE

Company seeks priority review of NOVATRONE in secondary progressive Multiple Sclerosis

SEATTLE - Immunex Corporation (NASDAQ:IMNX) announced today that it has filed a supplemental NDA with the U.S. Food and Drug Administration (FDA) for expanded labeling for NOVANTRONE® (mitoxantrone for injection concentrate) for the treatment of patients with secondary progressive Multiple Sclerosis (MS).

"There are 120,000 patients with secondary progressive MS for whom there are still no approved treatment options," said Peggy V. Phillips, senior vice president, pharmaceutical development for Immunex. "Patients with this form of the disease experience a steady worsening of their neurological function which can result in loss of control over movement of limbs and impaired vision and speech. We are pleased to be filing this and we have asked the FDA for priority review."

The results of the pivotal NOVANTRONE Phase III data submitted to the FDA today showed that NOVANTRONE had a statistically significant impact on relapse rate and disability progression in patients with secondary progressive MS. These clinical data were corroborated by positive magnetic resonance imaging (MRI) data.

This multicenter, placebo-controlled, randomized, observer-blind study of 194 patients compared two doses of NOVANTRONE -- 12 mg/m2 and 5 mg/m2 - with placebo. Each treatment was administered by short, IV infusion once every three months for two years. These results were reported at the September 1998 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Additional third-year follow-up data were presented in April of this year at the Annual Meeting of the American Academy of Neurology (AAN). These results showed that one year after treatment was stopped, patients who had been treated with NOVANTRONE experienced a sustained reduction in their number of attacks, and delay in their disab
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
2-Jun-1999


Page: 1 2 3

Related medicine news :

1. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
2. Immunexs TRAIL Molecule Shows Potential As Anti-Tumor Agent
3. Mad hatters, seafood jubilees, & Pfiesteria Files
4. NOVANTRONE application for multiple sclerosis granted priority review by FDA

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology:
Cached News: